← Grant listing · GrantsDue Pro
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
National Institutes of Health · PAR-25-075 · Deadline: October 14, 2026 · Advertised ceiling: $250k
Opportunity-exact history — these numbers describe this specific funding opportunity (PAR-25-075), from NIH RePORTER.
to 1 distinct organizations. By FY: 2026: 1
range $327k – $327k
Listing summary
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens si…
Eligibility: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations (other), Nonprofits with 501(c)(3), other than higher education, Nonprofits without 501(c)(3), Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others · Categories: Education, Health · official listing ↗
The full brief adds winner tables, recipient breakdowns, the printable "prepared for your client" version, and CSV export — plus a matched-grants list for your client's profile. Client Packet $79 or Pro subscription →
Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.